This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Gary Musso, PhD
President at Musso and Associates LLC
Speaker

Profile

A goal-driven accomplished pharmaceutical executive with over fourty years of broad-based experience. Significant achievements in drug discovery, product development, product approval, drug delivery and regulatory affairs. Provides strategic vision for programs from inception/discovery phases through commercialization. Inventor of several patents and author of many successful regulatory filings and peer-reviewed publications. Expertise to transform science and technologies into clinically and commercially viable products in oncology, inflammation, neurology, and endocrinology. Currently, heading CMC technical and regulatory activities for multiple biotech organizations and strategic adviser to several others. Major contribution to the following approved drugs: Kyprolis®, Vyleesi®, Angiomax®, Tymlos®, Trulance®, Plenaxis®

Agenda Sessions

  • Workshop Leader’s Welcome and Opening Remarks

    1:30pm
  • CMC Regulatory Area for Peptides including EMA Draft Guidance on Synthetic Peptides

    3:30pm